Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

19,870.00
30 Sep 2014
Price Change (% chg)

-80.00₪ (-0.40%)
Prev Close
19,950.00₪
Open
19,710.00₪
Day's High
19,900.00₪
Day's Low
19,700.00₪
Volume
438,416
Avg. Vol
349,262
52-wk High
19,950.00₪
52-wk Low
12,800.00₪

TEVA.TA

Chart for TEVA.TA

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.71
Market Cap (Mil.): ₪190,218.30
Shares Outstanding (Mil.): 952.15
Dividend: 121.00
Yield (%): 2.40

Financials

  TEVA.TA Industry Sector
P/E (TTM): 17.87 33.26 33.98
EPS (TTM): 11.18 -- --
ROI: 7.47 18.14 17.39
ROE: 11.47 18.84 18.24
Search Stocks

CORRECTED-BRIEF-Teva Pharmaceutical present new data on MS drug Copaxone

(Corrects company name in headline to Teva Pharmaceutical from Teva Pharmaceuticals. Also, removes incorrect reference to Copaxone as an experimental MS drug)

11 Sep 2014

AbbVie, Teva broke law in AndroGel 'pay for delay' deal, U.S. says

WASHINGTON - The U.S. Federal Trade Commission on Monday sued Drugmakers AbbVie Inc and Teva Pharmaceuticals Industries Ltd for allegedly illegally preventing generic versions of AndroGel, for men with low testosterone, from getting to market.

08 Sep 2014

UPDATE 2-AbbVie, Teva broke law in AndroGel "pay for delay" deal, U.S. says

WASHINGTON, Sept 8 - The U.S. Federal Trade Commission on Monday sued Drugmakers AbbVie Inc and Teva Pharmaceuticals Industries Ltd for allegedly illegally preventing generic versions of AndroGel, for men with low testosterone, from getting to market.

08 Sep 2014

US FTC says AbbVie, Teva broke law in reaching AndroGel agreement

WASHINGTON, Sept 8 - Drug companies AbbVie Inc and Teva Pharmaceuticals Industries Ltd were sued by the U.S. Federal Trade Commission on Monday for allegedly illegally preventing generic production of AndroGel, used by men with low testosterone.

08 Sep 2014

UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca

08 Sep 2014

Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca

08 Sep 2014

UK court backs Teva rival to AstraZeneca lung drug

TEL AVIV - Teva Pharmaceutical Industries said Britain's High Court had handed down a positive judgment regarding its case against a patent for AstraZeneca's Symbicort lung drug.

03 Sep 2014

UPDATE 1-UK court backs Teva rival to AstraZeneca lung drug

TEL AVIV, Sept 3 - Teva Pharmaceutical Industries said Britain's High Court had handed down a positive judgment regarding its case against a patent for AstraZeneca's Symbicort lung drug.

03 Sep 2014

UK court backs Teva rival to AstraZeneca lung drug

TEL AVIV, Sept 3 - Teva Pharmaceutical Industries said Britain's High Court had handed down a positive judgment regarding its case against a patent for AstraZeneca's Symbicort lung drug.

03 Sep 2014

Teva finds positive results in advanced trials for asthma drug

TEL AVIV - Teva Pharmaceutical Industries said a drug under development had positive results in reducing the frequency of clinical asthma exacerbations in two advanced trials in patients with moderate to severe asthma.

02 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks